Table III.
Clinical trials of CAR-T/TCR-T cell therapy in NPC.
| Trial identifier | Phase | Treatment | Condition | Estimated enrollment | Completion date | Status | Location |
|---|---|---|---|---|---|---|---|
| NCT02980315 | Phase I/II | LMP1-CAR-T cells | EBV+ NPC | 20 | December 2017 | Unknown | China |
| NCT05239143 | Phase I | P-MUC1C-ALLO1 CAR-T cells |
Advanced or metastatic solid tumors including NPC | 100 | April 2039 | Recruiting | United States |
| NCT04107142 | Phase I | Haplo/allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T-cells | R/R solid tumor including NPC | 10 | March 2021 | Unknown | Malaysia |
| NCT05587543 | Early phase I | CAR-T/TCR-T cells | R/R EBV+ NPC | 24 | October 2030 | Not yet recruiting | China |
| NCT03648697 | Phase II | EBV-TCR-T (YT-E001) cells | R/M EBV+ NPC | 20 | October 2021 | Unknown | China |
| NCT04509726 | Phase I/II | EBV-specific TCR-T cell with cytokine auto-secreting element | R/M EBV+ NPC | 20 | August 2023 | Recruiting | China |
| NCT03925896 | Phase I | LMP2 antigen-specific TCR-T cells | R/M EBV+ NPC | 27 | August 2022 | Unknown | China |
CAR-T, chimeric antigen receptor-modified T; TCR-T, T cell receptor-engineered T; NPC, nasopharyngeal carcinoma; EBV, Epstein-Barr virus; LMP, latent membrane protein; MUC1C, mucin1 cell surface-associated C-terminal; NKG2DL, natural killer group 2D ligand; R/R, relapsed/refractory; R/M, recurrent/metastatic.